SCHEMBL1739891

SCHEMBL1739891

Nc1ccn([C@H]2C=C[C@@H](COP(=O)(O)O)O2)c(=O)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLG P54098 2/20 0.48
POLB P06746 1/20 0.48
POLA1 P09884 1/20 0.44
P2RY2 P41231 2/20 0.43
LMNA P02545 3/20 0.43
THRB P10828 1/20 0.43
MTOR P42345 1/20 0.43
MDM2 Q00987 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
ST6GAL1 P15907 4/20 0.42
PDE3A Q14432 3/20 0.41
CACNA1F O60840 2/20 0.41
ALB P02768 2/20 0.41
MAPT P10636 2/20 0.41
CACNA1D Q01668 2/20 0.41
CACNA1S Q13698 2/20 0.41
CACNA1C Q13936 2/20 0.41
TSHR P16473 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9856523 0.89 POLG (0.63) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL8644096 0.84 LMNA (0.45) POLGPOLBPOLA1P2RY2LMNA
SCHEMBL5821 0.81 LMNA (0.55) POLGPOLBPOLA1LMNATHRB
SCHEMBL1980249 0.81 LMNA (0.55) POLGPOLBPOLA1LMNATHRB
SCHEMBL7154210 0.81 LMNA (0.55) POLGPOLBPOLA1LMNATHRB
SCHEMBL14580321 0.81 LMNA (0.55) POLGPOLBPOLA1LMNATHRB
SCHEMBL31662024 0.80 LMNA (0.47) POLGPOLBPOLA1LMNATHRB
SCHEMBL10510561 0.80 HRAS (0.44) POLA1LMNATHRBMTORMDM2
SCHEMBL10512002 0.80 DUT (0.42) POLGPOLBPOLA1P2RY2LMNA
SCHEMBL10512094 0.78 NLRP3 (0.44) POLBPOLA1LMNATHRBMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9861652-B2 2′ Fluoronucleosides EMORY UNIVERSITY (US) 2018-01-09 US disclosed
US-20160158266-A1 2' FLUORONUCLEOSIDES EMORY UNIVERSITY 2016-06-09 US disclosed
US-9180138-B2 2′-fluoronucleosides UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2015-11-10 US disclosed
US-20130157971-A1 2'-FLUORONUCLEOSIDES SCHINAZI RAYMOND F (US) 2013-06-20 US disclosed
US-8168583-B2 2-fluoronucleosides UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2012-05-01 US disclosed
EP-2392580-A1 2'-fluoronucleosides Emory University (US) 2011-12-07 EP disclosed
EP-2390257-A1 2'-fluoronucleosides Emory University (US) 2011-11-30 EP disclosed
US-20110256952-A1 GOLF CLUB, SHAFT REPLACING METHOD AND HEAD REPLACING METHOD BRIDGESTONE SPORTS CO., LTD. (JP) 2011-10-20 US disclosed
US-20100173863-A1 2-Fluoronucleosides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-07-08 US disclosed
US-7662938-B2 2′-fluoronucleosides EMORY UNIVERSITY (US) 2010-02-16 US disclosed
US-20080300398-A1 2'-FLUORONUCLEOSIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-04 US disclosed
US-7307065-B2 2′-Fluoronucleosides EMORY UNIVERSITY (US) 2007-12-11 US disclosed
EP-1754710-A2 2'-Fluoroncucleosides Emory University (US) 2007-02-21 EP disclosed
US-6911424-B2 2′-fluoronucleosides EMORY UNIVERSITY (US) 2005-06-28 US disclosed
US-20040254141-A1 2'-Fluoronucleosides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-12-16 US disclosed
US-20020198171-A1 2'-fluoronucleosides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-12-26 US disclosed
US-6348587-B1 PURINE OR PYRIMIDINE BASE DERIVATIVES; ANTICANCER, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS; TREATING HIV AND HEPATITIS EMORY UNIVERSITY 2002-02-19 US disclosed
EP-0284405-A2 Anti-viral compounds, dosage forms and methods BAKER NORTON PHARMACEUTICALS, INC. (US) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198171-A1 2'-fluoronucleosides NSUN2, PNP, FDPS POLG 2013/4885POLB 815/4885POLA1 2168/4885
US-20040254141-A1 2'-Fluoronucleosides NSUN2, PNP, FDPS POLG 2013/4885POLB 815/4885POLA1 2168/4885
US-20100173863-A1 2-Fluoronucleosides PNP, BCL3, NPC1 POLG 1938/4885POLB 591/4885POLA1 1792/4885
US-20080300398-A1 2'-FLUORONUCLEOSIDES METTL3, BCL3, PNP POLG 3270/4885POLB 1511/4885POLA1 3591/4885
US-20160158266-A1 2' FLUORONUCLEOSIDES PNP, BCL3, NPC1 POLG 2001/4885POLB 589/4885POLA1 1744/4885
US-20130157971-A1 2'-FLUORONUCLEOSIDES PNP, BCL3, FUBP3 POLG 1914/4885POLB 465/4885POLA1 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.